NASDAQ:TLRY - US88688T1007 - Common Stock
We assign a fundamental rating of 2 out of 10 to TLRY. TLRY was compared to 193 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -105.42% | ||
ROE | -144.68% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 29.29% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.19 | ||
Debt/FCF | N/A | ||
Altman-Z | -1.11 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.46 | ||
Quick Ratio | 1.49 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 62.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:TLRY (8/27/2025, 9:48:09 AM)
1.4499
0 (-0.01%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.94 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.06 | ||
P/tB | 2.16 | ||
EV/EBITDA | 62.32 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -105.42% | ||
ROE | -144.68% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 29.29% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.19 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 11.15 | ||
Cap/Depr | 24.66% | ||
Cap/Sales | 4.01% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.46 | ||
Quick Ratio | 1.49 | ||
Altman-Z | -1.11 |